
Inventiva SA
IVAHealthcare|Biotechnology|France
$4.29
-0.21 (-4.66%)
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
1.65,
20.47,
119.77,
377.87,
844.17
],
"ebit_estimate": [
-108.44,
-110.33,
-39.35,
27.44,
244.4
],
"ebitda_estimate": [
-127,
-92.86,
-48.21,
-127.88,
null
],
"net_income_estimate": [
-162.47,
-185.58,
-174.45,
4.93,
304.18
],
"per_share_eps_estimate": [
-0.82,
-0.9,
-0.72,
-0.36,
0.73
],
"eps_nri_estimate": [
-0.77,
-0.9,
-0.72,
-0.36,
0.73
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
1.28,
null,
null,
null,
null
],
"pretax_income_estimate": [
-165.25,
-204.17,
-150.49,
8.69,
325.68
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
85,
85,
90,
90,
95
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
5.87
],
"long_term_growth_rate_mean": 27.33,
"long_term_revenue_growth_rate_mean": "230.41",
"future_per_share_eps_estimate_growth": 27.79,
"future_eps_nri_estimate_growth": 27.33,
"future_revenue_estimate_growth": 230.41,
"future_ebit_estimate_growth": 34.54,
"future_ebitda_estimate_growth": 47.22,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 21.46,
"future_pretax_income_estimate_growth": 24.25,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202612",
"202706",
"202712"
],
"revenue_estimate": [
null,
null,
null,
null
],
"ebit_estimate": [
-85.4,
-93.11,
-94.39,
-102.36
],
"ebitda_estimate": [
null,
null,
null,
null
],
"net_income_estimate": [
-85.4,
-93.11,
-94.39,
-102.36
],
"per_share_eps_estimate": [
-0.32,
-0.35,
-0.33,
-0.31
],
"eps_nri_estimate": [
-0.32,
-0.35,
-0.33,
-0.31
],
"dividend_estimate": [
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null
],
"pretax_income_estimate": [
-85.4,
-93.11,
-94.39,
-102.36
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
null
],
"long_term_growth_rate_mean": 27.33,
"long_term_revenue_growth_rate_mean": "230.41",
"future_per_share_eps_estimate_growth": 27.79,
"future_eps_nri_estimate_growth": 27.33,
"future_revenue_estimate_growth": 230.41,
"future_ebit_estimate_growth": 34.54,
"future_ebitda_estimate_growth": 47.22,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 21.46,
"future_pretax_income_estimate_growth": 24.25,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}